Check out the upcoming bomb in cancer treatment. Photochemical internalisation (PCI) is a technology developed to unlock the full potential of drugs by targeted illumination of a well-defined area of the body, following the administration of our proprietary product and the active drug. Since the effect occurs only where light is applied, PCI is a localised targeted therapy http://pcibiotech.no/
PCI has been shown to boost the effect of chemo, but also vaccines and antibiotics. I have invested 40% of my «speculation» capital in PCI Biotech. I consider this as a potential 50x or more, but it may take a year or two before ignition. The vaccination program is likely to be the first on the move and can actually happen any time soon. Data shows thar PCI on cancer vaccines can boost the effect 5-8 times of what is possible today. Results will be presented after the summer. You have been warned
Strong effect on antibiotics. http://amici.lifescienceopenspace.pl/wp-content/uploads/2019/04/Poster_Xiaolin-Zhang.pdf
Check the news ,Pcib becomes a winner http://pcibiotech.no/second-quarter-and-first-half-2019-results/
PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer (RELEASE) https://clinicaltrials.gov/ct2/show/NCT04099888
Check these results. http://pcibiotech.no/wp-content/uploads/2019/11/PCI-Biotech-BIO_Europe-Nov-2019.pdf
Pcib is best when it comes to delivery. https://res.mdpi.com/d_attachment/jcm/jcm-09-00528/article_deploy/jcm-09-00528.pdf
AstraZeneca is in talks with Pcib about the Nac section delivery. We now see that they are looking for people who are specialists in the subject. Taking place here big things can happen soon. https://www.linkedin.com/jobs/view/1704647887 https://www.astrazeneca.com/what-sc...generation-of-drug-delivery-technologies.html
The US patent covers the use of fimaVacc in combination with a new important class of vaccine adjuvants called toll like receptor agonists. Toll like receptor agonists (TLR agonists) is a diverse class of molecules that can be used for enhancing immune responses to several types of vaccines. TLR agonists have similarities to molecules present in various types of infectious agents, like viruses and bacteria, and can act as adjuvants to alert the immune system of a possible infection, thereby activating the immune system. The combination of TLR agonists with PCI Biotech’s vaccine technology, fimaVacc, has been shown to be effective for enhancing cellular immune responses that are important for the effect both of therapeutic and prophylactic vaccines. To our knowledge, this is the first study to show that vaccination with UV-inactivated whole virions plus TLR agonists provides protection against SARS-CoV infection without strong Th2 skewing; TLR stimulation reduced the high level of eosinophilic infiltration that occurred in the lungs of mice immunized with UV-V. TLR agonists are approved for human use (54), and several are currently in preclinical development for use as vaccine adjuvants (55).
Now it's time to buy https://www.pcibiotech.no/news/pci-...maporfin-in-the-treatment-of-bile-duct-cancer
